Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $273000.0.

  • Northwest Biotherapeutics' Share-based Compensation fell 6014.6% to $273000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year decrease of 6775.18%. This contributed to the annual value of $3.5 million for FY2024, which is 2159.71% down from last year.
  • Northwest Biotherapeutics' Share-based Compensation amounted to $273000.0 in Q3 2025, which was down 6014.6% from $364000.0 recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Share-based Compensation ranged from a high of $9.8 million in Q1 2021 and a low of $273000.0 during Q3 2025
  • For the 5-year period, Northwest Biotherapeutics' Share-based Compensation averaged around $1.9 million, with its median value being $1.2 million (2024).
  • Within the past 5 years, the most significant YoY rise in Northwest Biotherapeutics' Share-based Compensation was 1004571.43% (2021), while the steepest drop was 9675.39% (2021).
  • Over the past 5 years, Northwest Biotherapeutics' Share-based Compensation (Quarter) stood at $866000.0 in 2021, then surged by 195.27% to $2.6 million in 2022, then plummeted by 38.4% to $1.6 million in 2023, then plummeted by 71.17% to $454000.0 in 2024, then tumbled by 39.87% to $273000.0 in 2025.
  • Its Share-based Compensation stands at $273000.0 for Q3 2025, versus $364000.0 for Q2 2025 and $385000.0 for Q1 2025.